Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Cancer Experts Detail Advanced Radiosurgery Treatments for Lung Cancer Using Varian Medical Systems Technologies



 Cancer Experts Detail Advanced Radiosurgery Treatments for Lung Cancer Using
                     Varian Medical Systems Technologies

More than 800 oncology professionals at European Society for Radiotherapy and
Oncology forum hear of pioneering treatment delivery, motion management and
tumor-tracking technologies for tackling the growing lung cancer burden

PR Newswire

GENEVA, April 22, 2013

GENEVA, April 22, 2013 /PRNewswire/ -- Cancer experts have reported future
trends and progress in radiotherapy treatments for lung cancer using motion
management and tumor-tracking technologies from Varian Medical Systems (NYSE:
VAR). Speakers at Varian's Emerging Technologies Symposium at the annual ESTRO
conference detailed experiences of stereotactic ablative body radiotherapy
(SABR) treatments using Varian's TrueBeam™ medical linear accelerator and
Calypso® 'GPS for the Body' tumor-tracking technology.

Professor Suresh Senan, radiation oncologist at VU University Medical Center
(VUMC) in Amsterdam, the Netherlands, presented a systematic review¹ into
published outcomes of lung SABR treatments for central lung tumors at multiple
cancer centers globally. "This systematic review shows that SABR achieves high
local control with limited side effects, even for central lung tumors," he
said.

Prof. Senan also provided details of treatments at VUMC, where more than 1200
stage 1 lung tumor patients have been treated in the last ten years using
SABR.  The clinic, which receives referrals from more than 70 Dutch hospitals,
treats patients on eight Varian linear accelerators, including four TrueBeam
devices.  Since 2008, all lung SABR treatments at VUMC have been delivered
using Varian's RapidArc® technology, many on the TrueBeam system. According to
Professor Senan, the main benefit of RapidArc for lung patients is the shorter
treatment time with less risk of motion.

"This is especially important for SABR, where high doses are delivered over
fewer treatment sessions," he says. "With the introduction of TrueBeam
technology, the integration between imaging and treatment delivery has been
improved. Furthermore, delivery of the highest SABR doses using the High
Intensity Mode for lung tumors has reduced treatment delivery times to less
than four minutes."

Dr. Parag Parikh, assistant professor of radiation oncology at Washington
University in St. Louis, U.S., detailed the results of an ongoing clinical
trial using Calypso Anchored Beacon® transponders in lung cancer patients.²
  The trial is primarily intended to evaluate tumor localization with the
Calypso system for patients with implanted anchored transponders and to assess
the positional stability of the transponders throughout the treatment process.
"The data we have gathered so far shows that the implantation is safe and that
there is very little migration of the markers," said Dr. Parikh.

The Varian symposium was chaired by Dr. Marta Scorsetti, director of
radiotherapy and radiosurgery at the Humanitas Cancer Center in Milan, Italy,
where more than 300 lung cancer patients have been treated using a TrueBeam
treatment machine since its installation in July 2010.

The symposium commenced with Professor Philippe Lambin, head of radiation
oncology at the MAASTRO Clinic in Maastricht, the Netherlands, outlining the
need for software-based 'Decision Support Systems' (DSS) to allow
individualized treatments.

Such systems, he said, are particularly valuable because of the huge volume of
information that the modern clinician needs to assess. "With the help of DSS,
doctors are able to more objectively select the best individualized
treatment," said Prof. Lambin. "By utilizing a system which not only
integrates all diagnostic information and therapeutic options but also takes
into account the wishes of the patient, it's easier for medical professionals
to propose tailor-made treatment plans to patients."    

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading
manufacturer of medical devices and software for treating cancer and other
medical conditions with radiotherapy, radiosurgery, a Varian Oncology and
brachytherapy. The company supplies informatics software for managing
comprehensive cancer clinics, radiotherapy centers and medical oncology
practices. Varian is a premier supplier of tubes and digital detectors for
X-ray imaging in medical, scientific, and industrial applications and also
supplies high-energy X-ray devices for cargo screening and non-destructive
testing applications. Varian Medical Systems employs approximately 6,000
people who are located at manufacturing sites in North America, Europe, and
China and approximately 70 sales and support offices around the world. For
more information, visit http://www.varian.com or follow us on Twitter.

Devices mentioned in this press release may not have obtained regulatory
clearance yet or are currently not available in all markets.

¹ Senthi S et al. Outcomes of stereotactic ablative radiotherapy for central
lung tumours: A systematic review. Radiother Oncol (2013),
http://dx.doi.org/10.1016/j.radonc.2013.01.004

² 510k pending

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

SOURCE Varian Medical Systems

Website: http://www.varian.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement